The reporter learned from Dongyang Pharmaceutical that the company achieved commercial delivery of glycine insulin injections approved by the US FDA in April of this year. The first batch of 1.152 million tablets was sold in the US. Currently, it has locked in more than 18 million overseas orders. This product is also the first insulin product in China to enter the US market.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.